Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.80 [0.61, 1.05] | | < 1 | | 0% | 1 study (1/-) | 94.6 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.77 [0.59, 1.01] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | important | - |
objective responses (ORR) | 2.43 [1.05, 5.65] | | > 1 | | 0% | 1 study (1/-) | 98.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.59 [0.20, 1.69] | | < 1 | | 0% | 1 study (1/-) | 83.8 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.70 [0.43, 1.12] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.41 [0.52, 3.82] | | < 1 | | 0% | 1 study (1/-) | 25.1 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.09 [0.58, 2.03] | | < 1 | | 0% | 1 study (1/-) | 39.7 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.76 [1.04, 2.99] | | < 1 | | 0% | 1 study (1/-) | 1.8 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.39 [0.22, 0.69] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.49 [0.29, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 1.81 [0.81, 4.05] | | < 1 | | 0% | 1 study (1/-) | 7.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.21 [0.02, 2.02] | | < 1 | | 0% | 1 study (1/-) | 91.1 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 3.86 [0.19, 77.90] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.63 [0.09, 4.55] | | < 1 | | 0% | 1 study (1/-) | 67.5 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.24 [0.37, 28.15] | | < 1 | | 0% | 1 study (1/-) | 14.4 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.47 [0.10, 2.13] | | < 1 | | 0% | 1 study (1/-) | 83.6 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.92 [0.20, 18.73] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.27 [0.11, 14.23] | | < 1 | | 0% | 1 study (1/-) | 42.2 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.63 [0.04, 10.24] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.10 [0.01, 2.08] | | < 1 | | 0% | 1 study (1/-) | 92.8 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.03 [0.00, 0.45] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 6.52 [0.35, 120.50] | | < 1 | | 0% | 1 study (1/-) | 10.6 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.32 [0.01, 9.50] | | < 1 | | 0% | 1 study (1/-) | 74.3 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.31 [0.03, 3.50] | | < 1 | | 0% | 1 study (1/-) | 82.5 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.50] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.32 [0.01, 9.50] | | < 1 | | 0% | 1 study (1/-) | 74.3 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |